A case-control study of hormone replacement therapy after primary surgical breast cancer treatment

European Journal of Surgical Oncology

Volumn 25, Issue 2, 1999, Pages 146-151

  Uršič Vrščaj, Marjetka ^a   Bebar, Sonja ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Breast cancer; Cancer; Hormone replacement therapy; Menopause

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; HORMONE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; PRIORITY JOURNAL; RELAPSE; RISK; TUMOR VOLUME;

EID: 0344177543     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1998.0617     Document Type: Article

References (47)

1. Trope C, Iversen O-E. Breast cancer: epidemiology, effect of hormone treatment, treatment of breast cancer-patients with estrogen. CME J Gynecol Oncol 1996; 1: 68-70.
2. Cancer Incidence in Slovenia. Ljubljana: Cancer Registry of Slovenia, Report No 36, 1994.
3. Fenlon D. Menopause: a problem for breast cancer patients. Eur J Care 1996; 4: 166-72.
4. European Consensus Development Conference. Montreaux, Switzerland, 1996.
5. Practical Guidelines for General Practitioners. Bray-on-Thames: Excerpta Medica, 1995.
6. Nachtigall L, Nachtigall R, Nachtigal RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9.
7. Hammond CB, Jolovsek FR, Lee RD, et al. Effects of long-term estrogen replacement therapy. II: neoplasia. Am J Obstet Gynecol 1979; 133: 537-47.
8. Nachtigall L, Nachtigall R, Nachtigal RD, Beckman EM. Estrogen replacement therapy. I. A 10-year prospective study in the relationship of osteoporosis. Obstet Gynecol 1979; 53: 277-81.
9. Hammond CB, Jolovsek FR, Lee RD, et al. Effects of long-term estrogen replacement therapy. I: metabolic effects. Am J Obstet Gynecol 1979; 133: 525-36.
10. Bush TL, Barret-Connor E, Cowen DK, et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102.
11. Henderson BE, Padanini-Hill A, Ross RK, et al. Estrogen replacement and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159: 312.
12. Creasman WT. Hormone replacement therapy (HRT) and cancer. CME J Gynecol Oncol 1996; 1: 6-73.
13. Sands R, Boshoff C, Jones A, Studd J. Current opinion: hormone replacement therapy after a diagnosis of breast cancer. Menopause 1995; 2: 73-80.
14. Gambrell RD. Hormone replacement therapy in patients with previous breast cancer. Menopause 1995; 2: 55-7.
15. Giacalone PL, Laffargue F. Treatment hormonal substitutif apres cancer du sein. Contracept Fertil Sex 1994; 22: 741-5.
16. Bebar S, Uršič-Vrščaj M. Advantages and disadvantages of hormone replacement therapy. Radiol Oncol 1996; 30: 210-3.
17. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogen and progestin and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93.
18. Craig J. Antiestrogens: past, present and future. Oncology 1997; Suppl. 1.
19. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogenprogestin hormone replacement therapy in relation to risk of breast cancer in middle aged women. JAMA 1995; 274: 137-42.
20. Uršič-Vrščaj M, Bebar S. Influence of exogenous hormones on the recurrence and progression of cancer. Radiol Oncol 1996; 30: 271-4.
21. Creasman WT. Hormone replacement therapy in breast cancer. CME J Gynecol Oncol 1996; 1: 64-6.
22. DisSaia PJ, Odicino F, Grosen EA, et al. Hormone replacement therapy in breast cancer. Letter to the editor. Lancet 1993; 342: 1232.
23. Berguist L, Adami HO, Persson I, Bergstom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestagen replacement therapy. Am J Epidemiol 1992; 130: 221-8.
24. Gamrell RD Jr. Role of progestagens in the prevention of breast cancer. Maturitas 1986; 8: 169.
25. Calle EE, Miracle-Memahill HL, Thun MJ, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of post-menopausal women. J Natl Cancer Inst 1995; 87: 517-23.
26. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust 1995; 162: 491-3.
27. Smith DC, Prentice R, Thompson DJ, Hermann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 203: 1164.
28. Ziel HK, Kinkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1976; 293: 1167.
29. Gamrell RD. Prevention of endometrial cancer with progestagens. Maturitas 1986; 8: 159-68.
30. Koss LG, Schreiber K, Oberlander SG, et al. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984; 64: 1.
31. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-4.
32. Creasman WT, Henderson D, Hinshaw W, Clarke-Person D. Estrogen replacement in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67: 326-30.
33. Baker DP. Estrogen replacement therapy in the patient with previous endometrial carcinoma. Compreh Therapy 1990; 16: 28-35.
34. Lee RB, Burke T, Park RC. Estrogen replacement therapy following treatment for Stage I endometrial carcinoma. Gynecol Oncol 1990; 36: 189-91.
35. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer. Cancer Causes Control 1994; 5: 359-66.
36. Gerhardsson-de-Verdier M, London S. Reproductive factors, exogenous female hormones, and colorectal cancer 1990 by subsite. Cancer Causes Control 1992; 3: 355-60.
37. Furner SE, Davis FG, Nelson RL, Haenszel W. A case control study of large bowel cancer and hormone exposure in women. Cancer Res 1989; 49: 4936-40.
38. Lauritzen C. Ostrogensubstitution in der Postmenopause vor und nacht behanddeltem Genital-ubd Mammerkarzinom. In: Lauritzen C (ed). Menopause Hormonsubstitution Heute. Basel: Aesopus Verlag, 1983: 76-88.
39. Wu-Williams AH, Lee M, Whittemore AS, et al. Reproductive factors end colorectal risk among chinese females. Cancer Res 1991; 51: 2307-11.
40. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large bowel cancer. J Natl Cancer Inst 1995; 87: 1067-71.
41. Calle EE, Miracle-Memahill HL, Thun MJ, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of post-menopausal women. J Natl Cancer Inst 1995; 87: 517-23.
42. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-59.
43. Marchant DJ. Estrogen-replacement therapy after breast cancer. Risks versus benefits. Cancer 1993; 71: 2169-76.
44. Eden JA. Oestrogen and the breast. 1. Myths about oestrogen 49. DiSaia PJ. Hormone-replacement therapy in patients with breast cancer: a reappraisal. Cancer 1993; 71: 1490-500.
45. Eden JA, Bosh T, Nand S. Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67-72.
46. Vassilopoulou-Sellin R, Theriault RL, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65: 89-93.
47. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen - replacement therapy in women with a history of breast cancer. Monogr Natl Cancer Inst 1994; 16: 153-9.